Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
What Is Ophthalmia Neonatorum? | OBN
Ophthalmia neonatorum, also known as neonatal conjunctivitis, is an inflammation of the conjunctiva (the clear membrane covering the white part of the eye) that occurs in newborns. It is a serious condition that can lead to blindness if left untreated.…
Alcon Launches PRECISION7 One-Week Contact Lens
Alcon has announced the U.S. launch of PRECISION7, a groundbreaking contact lens designed for a convenient one-week replacement cycle. Incorporating the advanced 7-day ACTIV-FLO system, these lenses offer up to 16 hours of comfort and clear vision, even on the…
Tarsus Appoints Dr. Elizabeth Yeu as Chief Medical Officer
Tarsus Pharmaceuticals has announced the appointment of Elizabeth Yeu, MD, as Chief Medical Officer, effective November 4, 2024. Dr. Yeu, an esteemed ophthalmologist with over two decades of clinical and leadership experience, will lead the company’s medical organization and oversee…
Formosa: Positive Phase 3 Results for APP13007 in China
Formosa Pharmaceuticals recently announced the completion of CPN-303, a Phase 3 clinical trial conducted in Chinese cataract surgery patients to evaluate APP13007 (GPN00833). This trial, managed by Formosa’s licensee Grand Pharma (0512.HK), demonstrated positive top-line results, showcasing APP13007’s effectiveness in…
Konan Medical Launches objectiveFIELD Visual Analyzer| OBN
Konan Medical USA has officially launched the objectiveFIELD (OFA) visual field analyzer, a new device that enhances visual field testing by utilizing pupillary responses rather than traditional patient-reliant methods. A Breakthrough in Visual Field Testing: The OFA The objectiveFIELD (OFA)…
GenSight: Lumevoq Most Effective for ND4-LHON
GenSight Biologics recently published a meta-analysis focused on assessing the efficacy of various treatments for Leber Hereditary Optic Neuropathy (LHON) due to the MT-ND4 mitochondrial gene mutation, known as ND4-LHON. The study, which appears in Survey of Ophthalmology, represents a…
Neurotech FDA Update on NT-501 MacTel Treatment| OBN
Neurotech Pharmaceuticals has released an update regarding its biologics license application (BLA) for NT-501 (revakinagene taroretcel), a treatment designed for macular telangiectasia type 2 (MacTel). The U.S. Food and Drug Administration (FDA) has recently extended the Prescription Drug User Fee…
FDA Fast Tracks FLQ-101 for Retinopathy of Prematurity
The U.S. FDA has granted fast track designation to FLQ-101, FELIQS’ oral and intravenous solution targeting retinopathy of prematurity (ROP). This designation will accelerate the regulatory review process for FLQ-101, a promising treatment for a condition currently lacking approved preventative…
FDA Approves LumiThera’s Valeda for Dry AMD Treatment
The U.S. FDA has granted LumiThera authorization to market its Valeda Light Delivery System, the first FDA-authorized device designed to treat vision loss in patients with dry age-related macular degeneration (AMD). This significant approval, obtained through the De Novo authorization…
Genentech: Vabysmo Effective for Diverse DME Patients
Genentech recently announced encouraging one-year results from its phase 4 ELEVATUM study evaluating Vabysmo (faricimab-svoa) for diabetic macular edema (DME) in racially and ethnically underrepresented populations. The findings, presented at the American Academy of Ophthalmology (AAO) 2024 annual meeting in…